openPR Logo
Press release

Weitz & Luxenberg Lawyers Respond to Study Casting Further Doubt on Avandia

10-02-2007 01:32 PM CET | Politics, Law & Society

Press release from: Weitz & Luxenberg

A leading plaintiffs’ litigation law firm in America

A leading plaintiffs’ litigation law firm in America

October 1, 2007, New York, NY— A further pall has been cast over Avandia, a drug for Type 2 diabetes. A new study has found that long-term use of the pharmaceutical increases heart attack risk by more than 40 percent and doubles the chance of heart failure. These findings are nearly identical to that of another recent scientific analysis out this spring.

“Millions of people with diabetes trusted Avandia to help control the disease,” said Perry Weitz, founding partner of Weitz & Luxenberg, P.C. “These individuals should have been informed much earlier on about the serious cardiovascular risks.”

Drug giant GlaxoSmithKline Plc, maker of Avandia, had been warned by U.S. regulators as early as 2001 against attempting to play down the risk of cardiac disease associated with Avandia in its marketing materials. Additionally, the Food and Drug Administration only announced in June that the toughest so-called “black box warning” label would be placed on Avandia—this is more than a year after FDA safety reviewers reportedly recommended taking that urgent step.

Concern over the safety of Avandia only reached the public in May 2007, when the New England Journal of Medicine published a combined analysis of more than 40 studies. That report, widely covered by mainstream media, found that Avandia significantly raised the risks of heart attacks.

The new analysis, by researchers from Wake Forest University Baptist Medical Center and published in the September 12 issue of the Journal of the American Medical Association, is one of the first to evaluate how long-term use of Avandia affects risk of heart attacks, heart failure and mortality. The four studies involved followed more than 14,000 patients for at least a year. Researchers found that long-term use of Avandia (known generically as rosiglitazone) increased the risk of heart attack by 42 percent and doubled the risk of heart failure.

Lead author on the study, Sonal Singh M.D., estimated that 3.5 million patients in the U.S. take Avandia for diabetes. In a Wake Forest press release, Singh said the study’s findings suggest that Avandia “may cause more than 4,000 excess heart attacks and 9,000 excess cases of heart failure a year.”

People who have been injured after ingesting Avandia or any other medication, can contact Weitz & Luxenberg, P.C. Interested parties should visit our website at or e-mail You may also call Dave Kufeld in the Client Relations department at 1 (800) 476-6070. Our address is 180 Maiden Lane, New York, NY 10038

About Weitz & Luxenberg, P.C.:
Weitz & Luxenberg, founded in 1986, is one of the leading plaintiffs’ litigation law firms in America. The firm has played leading roles in national and local litigations involving asbestos, medical malpractice, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE and mercury, among other toxins. The firm has won numerous cases involving dangerous pharmaceuticals, including Vioxx, achieving a $13.5 million verdict against Merck & Co. (docket No. ATLL129605). The firm’s other active pharmaceutical litigations include actions against the manufacturers of Bextra, Celebrex, Ortho Evra and Seroquel.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Weitz & Luxenberg Lawyers Respond to Study Casting Further Doubt on Avandia here

News-ID: 29595 • Views:

More Releases from Weitz & Luxenberg

Weitz & Luxenberg Cited for Top NYS 2014 Product Liability Cases by New York Law …
Weitz & Luxenberg, P.C. has been recognized by the New York Law Journal for winning the top three product liability verdicts in New York State in 2014. “The lawyers and law firms who are ranked in this special section represent the best of the best in 2014,” New York Law Journal associate publisher Farrell McManus wrote in the Journal’s “Top Verdicts New York 2014.” He continued, “Their zealous advocacy on
Mesothelioma Treatment Tomudex Receives International Support
Mesothelioma Treatment Tomudex Receives International Support
Mesothelioma treatment Tomudex, made by a global pharmaceutical company, is receiving approval from a panel of international experts. Tomudex falls in the group of anti-cancer drugs known as antineoplastics. It prevents cell growth. By doing so, it leads to the elimination of tumors. In a study examining people diagnosed with pleural mesothelioma, the use of Tomudex in conjunction with Platinol resulted in improved response rates of 23.6% as opposed to
New Mesothelioma Treatment Technique Developed
New Mesothelioma Treatment Technique Developed
Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School. The surgical technique was applied on a mesothelioma patient
Mesothelioma Cancer: Possible Treatment Option
Mesothelioma Cancer: Possible Treatment Option
An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose. The use of a genetically engineered virus to disrupt the function

All 5 Releases

More Releases for Avandia

Future and Growth of BRIC Diabetes Drugs Market by 2021
Diabetes drugs help in preventing complications and controlling blood glucose level in the blood. Some of the drugs used to treat type 2 diabetes are metformin, actos, avandia, lantus subcutaneous, and invokana. All drugs are administered orally except insulin, exenatide, liraglutide, and pramlintide. Insulin is delivered through insulin delivery devices including infusion pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long acting, intermediate acting, short acting, and rapid
GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits
Nadrich & Cohen, LLP reports that GlaxoSmithKline has agreed to settle approximately 20,000 Avandia side effects lawsuits. Los Angeles, CA, February 3, 2012 – UK drug-maker GlaxoSmithKline has agreed to settle 20,000 Avandia side effects lawsuits. According to a Bloomberg report, the company previously agreed to pay at least $700 million to settle more than 15,000 claims on behalf of patients who said that the drug caused heart attacks, strokes
Pfizer Seeking Consolidation of Zoloft Birth Defects Lawsuits
Nadrich & Cohen, LLP reports that Pfizer is seeking to consolidate a number of federal Zoloft birth defects lawsuits into a multidistrict litigation. Los Angeles, CA, February 1, 2012 – Pfizer has reportedly asked a federal judicial panel to centralize a number of Zoloft birth defects lawsuits filed against the company. If the motion is granted, the cases would be consolidated for pretrial proceedings and heard in a federal district
Bristol-Meyers Squibb Sued by 72 Plaintiffs Over Plavix Side Effects
Nadrick & Cohen, LLP reports that 72 plaintiffs have joined together in a Plavix side effects lawsuit filed against Bristol-Meyers Squibb. Los Angeles, CA, January 27, 2012 – Seventy-two plaintiffs from across the country have joined together in filing a Plavix side effects lawsuit against the drug’s maker, Bristol-Meyers Squibb. According to the Madison Record, the plaintiffs are seeking an unspecified amount of compensation for injuries they say were caused
Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the